<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137874">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01921881</url>
  </required_header>
  <id_info>
    <org_study_id>AKF-385</org_study_id>
    <nct_id>NCT01921881</nct_id>
  </id_info>
  <brief_title>Does the Natural Medicinal Plant St John's Wort Affect the Glucose Tolerance in Healthy Individuals</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern Denmark</source>
  <oversight_info>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to examine if healthy individuals that ingest St John's wort will
      have a significantly difference in glucose tolerance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Glucose area under curve (AUC) 0-2 hours</measure>
    <time_frame>Glucose concentration 0, 15, 30, 45, 60, 90 and 120 after glucose ingestion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>At time=0, the subjects will ingest 75g glucose. Plasma glucose will be measured at 0, 15, 30, 45, 60, 90 and 120 minutes after glucose ingestion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>St John's wort pharmacokinetics</measure>
    <time_frame>At time=0</time_frame>
    <safety_issue>No</safety_issue>
    <description>At time=0, the concentration of active components hypericin and hyperforin will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other metabolic markers</measure>
    <time_frame>At time points, 0, 15, 30, 45, 60, 90, 120 minutes after glucose ingestion</time_frame>
    <safety_issue>No</safety_issue>
    <description>C-peptide and serum insulin will also be measured during the oral glucose tolerance test.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>St John's wort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo 3 oral glucose tolerance tests:
Without taking any St John's wort
After 3 weeks pretreatment with St John's wort
Minimum 6 weeks after last St John's wort ingestion</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>St John's wort</intervention_name>
    <arm_group_label>St John's wort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-40 years

          -  Males

          -  Fasting plasma-glucose &lt; 7.0 mmol/L

          -  Glycosylated haemoglobin A1c within reference or clinically insignificant deviation
             hereof

          -  Body mass index &lt; 30 kg/m^2

        Exclusion Criteria:

          -  Hypersensitivity to St John's wort

          -  Chronical or daily alcohol abuse

          -  Known liver disease

          -  Ingestion of drugs requiring prescription, except locally acting drugs
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Br√∏sem, Professor, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Southern Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Per Damkier, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tore B. Stage, MSc Pharm</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tore B. Stage, MSc Pharm</last_name>
    <phone>+45 6550 3678</phone>
    <email>tstage@health.sdu.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Institute of Public Health, University of Southern Denmark</name>
      <address>
        <city>Odense C</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tore B. Stage, MSc Pharm</last_name>
      <phone>+45 6550 3678</phone>
      <email>tstage@health.sdu.dk</email>
    </contact>
    <investigator>
      <last_name>Per Damkier, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tore B. Stage, MSc Pharm</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 1, 2013</lastchanged_date>
  <firstreceived_date>August 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern Denmark</investigator_affiliation>
    <investigator_full_name>Tore B. Stage</investigator_full_name>
    <investigator_title>MSc Pharm</investigator_title>
  </responsible_party>
  <keyword>Glucose tolerance</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
